Austria, UKUK

GE Healthcare acquires PAA Laboratories

17.08.2011

London/Pasching –GE Healthcare vamps up its biopharmaceutical capabilities. The U.K. based unit of the U.S. technology giant General Electric, announced that it has reached an agreement to acquire the Austrian PAA Laboratories. PAA Laboratories develops and manufactures cell culture products such as media, sera, growth supplements and reagents for use in biomedical research and in the production of protein-based pharmaceuticals. GE Healthcare hopes that, with PAA, it will be able to build an integrated platform for biomedical and cellular research as well as for bio-manufacturing. "The strong strategic fit between the two businesses, combined with expanded capabilities in product development and marketing, will offer significant long-term customer benefits," the company said in a statement. The deal is expected to be closed by the third quarter of 2011, financial details were not disclosed. According to BCC Research, the global demand for media, sera and reagents for cell culture is expected to grow from USD 2.3 billion in 2009 to USD 3.9 billion by 2015.

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1983

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/ge-healthcare-acquires-paa-laboratories.html

Image Gallery

Stock list

All quotes

TOP

  • RENEURON (UK)3.60 GBP13.6%
  • EPIGENOMICS (D)5.74 EUR10.4%
  • PROTHENA PLC (IE)36.95 USD9.5%

FLOP

  • CYTOS (CH)0.13 CHF-18.8%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • THERAMETRICS (CH)0.10 CHF-9.1%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.82 EUR39.0%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.13 CHF-95.2%
  • BIONOR PHARMA (N)2.18 NOK-45.5%
  • DIAGENIC (N)0.78 NOK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6275.0%
  • IXICO (UK)67.00 GBP740.7%
  • PLETHORA (UK)10.62 GBP658.6%

FLOP

  • CYTOS (CH)0.13 CHF-96.8%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.95 CHF-71.1%

No liability assumed, Date: 24.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper